CNBC July 31, 2024
Ashley Capoot

Key Points

– 23andMe CEO Anne Wojcicki has submitted a proposal to take the genetic testing company private.

– She is prepared to acquire all of 23andMe’s outstanding shares of common stock in cash for 40 cents per share, according to a filing with the SEC on Wednesday.

– 23andMe has struggled to generate steady recurring revenue since customers only needed to take its DNA test once to get their results.

Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private as its stock price continues to hover below $1.

Wojcicki said she was prepared to acquire all of 23andMe’s outstanding shares of common stock in cash for 40 cents per share, according to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article